Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Vitamin E reduces rate of decline in mild to moderate Alzheimer’s

  • Print
  • Comment
  • Save

Vitamin E supplementation reduces the rate of functional decline in patients with Alzheimer’s, shows a new study in JAMA.

The US double-blind, placebo-controlled, randomised trial included 613 participants with mild to moderate Alzheimer’s disease. Participants received either 2000 IU/d of vitamin E (alpha tocopherol) (n=152), 20 mg/d of memantine (n= 155), the combination (n=154), or placebo (n=152). The primary outcome measure was the participants’ Alzheimer’s disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score.

During the mean follow-up period of 2.27 years, participants receiving vitamin E alone had slower decline than those receiving placebo, as measured by the ADCS-ADL. There was a delay in clinical progression of 19% per year compared with placebo, which is approximately 6.2 months over the follow-up period. There was no difference in decline between patients on the vitamin E/memantine combination and placebo.

The researchers note that the findings ‘suggest benefit of alpha tocopherol in mild to moderate Alzheimer’s disease by slowing functional decline’. 

Read more here.

Have your say

  • Print
  • Comment
  • Save